Skip to content
Clinical Trials – home

Hypoplastic left heart syndrome Basic Information

1 / 1 trials open to patients1 country

In short

Hypoplastic left heart syndrome is a rare and complex heart condition that affects babies even before they are born, leaving the left side of the heart too small to pump blood properly to the body. This condition represents one of the most challenging heart defects that newborns can face, but thanks to advances in medical care and surgical techniques, many children with this condition are now surviving and living fuller lives than ever before.

Key points

  • Hypoplastic left heart syndrome affects approximately 1 in 3,800 babies in the United States, making it rare but still the most common single-ventricle heart defect.
  • The condition develops during the first eight weeks of pregnancy when critical structures on the left side of the heart fail to form properly, but there is nothing parents can do to prevent it.
  • Babies with HLHS often look healthy at birth, but symptoms typically appear within hours or days as natural fetal heart connections begin to close, making early detection crucial.
  • The right ventricle must do double duty in babies with HLHS, pumping blood to both the lungs and the entire body instead of just the lungs as it normally would.
  • Male babies are 1.5 times more likely than female babies to be born with HLHS, though researchers do not fully understand why this gender difference exists.
  • Many cases of HLHS can be diagnosed before birth through prenatal ultrasounds, allowing families to plan delivery at specialized cardiac centers equipped to provide immediate expert care.
  • Despite being considered universally fatal before the 1980s, advances in surgical techniques and medical care have dramatically improved survival rates, with many children now living into adulthood.
  • Emergency symptoms requiring immediate medical attention include blue or gray skin color, rapid breathing, weak pulse, cold extremities, poor feeding, and unusual sleepiness in newborns.

Understanding How Common This Condition Is

Hypoplastic left heart syndrome, often called HLHS, affects a small but significant number of babies each year. According to health statistics, approximately one out of every 3,800 to 3,955 babies in the United States is born with this condition. This translates to roughly 929 to 1,025 newborns diagnosed with HLHS annually across the country. While these numbers might seem small, HLHS accounts for about 2% to 3% of all congenital heart defects, which are heart problems present at birth. Despite being relatively rare, this condition is responsible for a disproportionately high number of heart-related deaths in the first week of life, accounting for approximately 23% of all cardiac deaths during this critical period.

The condition shows a clear pattern when it comes to which babies are affected. Boys are diagnosed with HLHS more frequently than girls, with male infants being about 1.5 times more likely to develop this heart defect. Interestingly, research has shown a slight decrease in the reported cases of HLHS over recent decades, dropping from about 0.689 cases per 1,000 births in the late 1990s to approximately 0.475 cases per 1,000 births by 2017. This decline is thought to be related to better prenatal detection methods and improved counseling for families during pregnancy, rather than an actual decrease in how often the condition occurs.

What Causes Hypoplastic Left Heart Syndrome

The exact cause of hypoplastic left heart syndrome remains largely unknown in most cases, which can be frustrating for families seeking answers. The condition develops during the first eight weeks of pregnancy when the baby's heart is forming in the womb. During this critical time, the structures on the left side of the heart fail to develop properly, resulting in underdeveloped or completely closed valves, a tiny left pumping chamber, and a narrowed main blood vessel leading from the heart.

Scientists believe that HLHS likely results from a combination of factors rather than a single cause. Genetics appears to play a role in some families, as researchers have identified specific genes that may increase the risk when they contain mutations or changes. Two genes in particular, called GJA1 and NKX2-5, have been linked to higher rates of HLHS when they are altered. Additionally, some babies with certain genetic disorders are more likely to have HLHS alongside their other health conditions. For example, children with Turner syndrome, a chromosomal condition affecting girls, or trisomy 18, a severe genetic disorder, may also have this heart defect.

However, it is important to understand that most babies born with HLHS have no family history of congenital heart disease. The condition appears to occur by chance in the majority of cases, without any clear reason or preventable cause. This means that parents cannot do anything during pregnancy to prevent HLHS from developing, and there is nothing they did or did not do that caused the condition. Some research suggests that a combination of genetic predisposition and environmental factors during pregnancy might contribute to the development of HLHS, but the specific environmental factors have not been clearly identified.

Risk Factors and Who Is Most Affected

While the causes of HLHS remain unclear, certain factors have been identified that may increase the likelihood of a baby being born with this condition. The most significant risk factor is genetic, with some families showing a tendency toward developing HLHS across generations. If a family has already had one child with HLHS, there may be a slightly higher chance of having another child with a similar heart defect, although this risk is still relatively low.

Babies with certain chromosomal abnormalities or genetic syndromes face higher risks of having HLHS as part of their overall health challenges. These conditions affect how the body develops during pregnancy and can impact multiple organ systems, including the heart. Beyond genetics, researchers have explored whether factors in the mother's environment, diet, or medication use during pregnancy might contribute to HLHS risk, but no specific modifiable risk factors have been definitively proven. This means that expectant mothers cannot take specific preventive measures to reduce the risk of their baby developing HLHS.

Gender appears to be another factor, with male babies consistently showing higher rates of HLHS compared to female babies. The reasons for this gender difference are not well understood but may relate to how male and female fetuses develop differently during pregnancy. The condition can occur in any ethnic or racial group and is not limited to any particular geographic region or socioeconomic status.

Recognizing the Symptoms

Babies with hypoplastic left heart syndrome often appear healthy immediately after birth, which can make the condition particularly dangerous if it has not been diagnosed during pregnancy. The symptoms typically develop within the first few hours or days of life, as normal changes occur in the newborn's circulation. Understanding these warning signs is crucial because early recognition and treatment are essential for survival.

One of the most noticeable symptoms is cyanosis, which is a bluish or grayish discoloration of the skin, lips, and nails. This happens because the baby's blood does not contain enough oxygen. The blue or gray color may appear differently depending on the baby's natural skin tone, being more obvious in lighter-skinned babies and appearing as a grayish tone in darker-skinned infants. Parents might also notice that their baby has trouble breathing, with rapid or labored breaths that indicate the heart is struggling to pump blood effectively.

Feeding difficulties are another common sign of HLHS. Babies may show poor sucking, tire quickly during feedings, or refuse to eat. This happens because the effort required to feed is too demanding for a heart that cannot pump efficiently. Parents might observe that their baby seems unusually sleepy, unresponsive, or lacking in energy, a state doctors call lethargy. The baby may also have fewer wet diapers than expected, indicating that the kidneys are not receiving adequate blood flow.

Physical examination may reveal additional concerning signs. The baby's skin might feel cool, clammy, or sweaty to the touch, particularly on the hands and feet. These extremities may feel cold because blood is not reaching them properly. The baby's pulse may be weak or rapid, and in some cases, the pulse in the feet may be particularly difficult to detect. As the condition worsens, babies can develop signs of shock, which is a life-threatening emergency. Shock can lead to seizures, kidney failure, and liver failure if not treated immediately.

Prevention Possibilities and Screening

Unfortunately, there are no known ways to prevent hypoplastic left heart syndrome from developing. Because the exact causes remain unclear and the condition develops early in pregnancy before many women even know they are expecting, there are no lifestyle changes, dietary supplements, or medical interventions that can reduce the risk of HLHS. The condition is not caused by anything the mother did or did not do during pregnancy, and it cannot be prevented through prenatal vitamins, avoiding certain foods, or any other preventive measure currently available.

However, early detection through prenatal screening has become increasingly common and valuable. Many cases of HLHS can be identified during routine pregnancy ultrasounds, typically during the second trimester around 20 weeks of gestation. When a basic ultrasound suggests a possible heart abnormality, doctors can perform a more detailed examination called a fetal echocardiogram. This specialized ultrasound focuses specifically on the baby's heart and can accurately diagnose HLHS before birth. Prenatal diagnosis allows families time to prepare emotionally, learn about the condition, and make informed decisions about delivery and treatment plans.

When HLHS is diagnosed before birth, healthcare teams usually recommend that the mother give birth at a hospital equipped with a specialized cardiac surgery center. This ensures that the baby has immediate access to the expert care needed from the moment of delivery. Having a baby with HLHS at a facility without cardiac specialists can be dangerous because these newborns require urgent medical treatment to survive. Prenatal diagnosis also allows families to meet with pediatric cardiologists and cardiac surgeons before the baby is born, helping them understand what to expect and feel more prepared for the journey ahead.

How the Body Is Affected

To understand how hypoplastic left heart syndrome affects a baby's body, it helps to know how a normal heart works. In a healthy heart, blood returns from the body to the right side of the heart, which pumps it to the lungs to pick up oxygen. The oxygen-rich blood then flows to the left side of the heart, where the powerful left lower chamber called the left ventricle pumps it through the aorta, the body's largest blood vessel, to deliver oxygen to all organs and tissues.

In babies with HLHS, multiple structures on the left side of the heart are severely underdeveloped or completely absent. The left ventricle, which is normally the heart's strongest pumping chamber, is too small to effectively pump blood. The mitral valve, which controls blood flow into the left ventricle, may be tiny or completely closed, a condition called atresia. Similarly, the aortic valve, which allows blood to flow from the left ventricle into the aorta, may also be too small or closed. The aorta itself and the aortic arch, the curved portion that carries blood away from the heart, are often narrow and underdeveloped.

Because the left side cannot function properly, babies with HLHS rely on unusual pathways to survive. Before birth and immediately after, blood can flow through two natural openings that exist in all fetal hearts: the foramen ovale, a hole between the upper heart chambers, and the patent ductus arteriosus, a blood vessel connecting the lung artery to the aorta. Through these connections, oxygen-rich blood from the lungs mixes with oxygen-poor blood and the right ventricle takes over the job of pumping to both the lungs and the body. This arrangement can work temporarily, but it is not sustainable.

The critical problem arises in the first days after birth when these fetal connections naturally begin to close, as they do in all healthy babies. When the ductus arteriosus starts to narrow and close, blood flow to the body becomes severely restricted. The right ventricle, which is not designed to handle the entire workload alone, becomes overwhelmed. Oxygen levels in the blood drop dangerously low, and vital organs including the brain, kidneys, and liver begin to suffer from inadequate blood supply. Without immediate medical intervention to keep these connections open and surgical repairs to create new pathways for blood flow, babies with HLHS cannot survive.

The body's response to this inefficient circulation creates additional problems. The heart beats faster trying to compensate for poor pumping, but this only puts more strain on the already overworked right ventricle. The lungs may receive too much blood flow, making breathing difficult and causing fluid to accumulate. Multiple organ systems can begin to fail as they are starved of oxygen-rich blood, leading to a cascade of life-threatening complications. This is why HLHS is considered one of the most critical congenital heart defects, requiring urgent and sophisticated medical and surgical interventions from the moment of diagnosis.

Did you know?

  1. Before the 1980s, hypoplastic left heart syndrome was considered universally fatal, but pioneering surgeon William Norwood developed a revolutionary three-stage surgical approach that changed the outlook completely, making survival into adulthood now possible for many patients.
  2. Babies with HLHS are born with what doctors call a "single-ventricle" heart, meaning they essentially function with only one working pumping chamber instead of two, yet with proper surgical repair they can live active lives.
  3. The right ventricle in babies with HLHS must work approximately twice as hard as normal because it pumps blood to both the lungs and the entire body, a job usually shared between the heart's two sides, making long-term heart function monitoring essential throughout their lives.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Hypoplastic left heart syndrome

Recruiting trials first

See all 1 trials →
Quick filters

1 clinical trial in this condition

Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Oxygen
  • Sponsor:Universitaetsklinikum Erlangen AöR
See all 1 trials →filters applied: condition = Hypoplastic left heart syndrome
Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).